Indicaciones terapéuticas del Meropenem
DOI:
https://doi.org/10.58713/rf.v1i2.2Palabras clave:
Meropenem, Carbapenems, Gramnegativos, Grampositivos, AnaerobiosResumen
Meropenem es un agente antibacteriano de amplio espectro de la familia de los carbapenémicos con actividad contra microorganismos gramnegativos, microorganismos grampositivos y anaerobios. Está indicado como tratamiento empírico previo a la identificación de organismos causales, o para la enfermedad generada por una o múltiples bacterias en adultos y niños con una amplia variedad de infecciones graves. No está indicado su uso en pacientes pediátricos menores de 3 meses. Este antibiótico sólo debe utilizarse como agente de reserva cuando falla la terapia convencional o cuando se ha documentado resistencia a otros antibióticos y únicamente existen presentaciones farmacéuticas para aplicación parenteral.
Citas
Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs. 2008;68(6):803-38. doi: 10.2165/00003495-200868060- 00006. PMID: 18416587.
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother. 2011;55(11):4943-60.
Craig W. A. (1997). The pharmacology of meropenem, a new carbapenem antibiotic. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 24 Suppl 2, S266–S275. https://doi.org/10.1093/ clinids/24.supplement_2.s266
Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008 Jan;9(1):23-37. doi: 10.1517/14656566.9.1.23. PMID: 18076336.
Raza A, Ngieng SC, Sime FB, Cabot PJ, Roberts JA, Popat A, Kumeria T, Falconer JR. Oral meropenem for superbugs: challenges and opportunities. Drug Discov Today. 2021 Feb;26(2):551- 560. doi: 10.1016/j.drudis.2020.11.004. Epub 2020 Nov13. PMID: 33197621.
Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67 (7): 1027-52
Merrem/MeronemTM (IV, 500mg, 1g): core data sheet. Astra Zeneca, 2006 Sep
Shah PM. Parenteral carbapenems. Clin Microbiol Infect. 2008 Jan;14 Suppl 1:175-80. doi: 10.1111/j.1469- 0691.2007.01868.x. Erratum in: Clin Microbiol Infect. 2008 May;14 Suppl 5:21-4. PMID: 18154543.
Hurst M, Lamb HM. Meropenem: a review of its use in patients in intensive care. Drugs. 2000;59(3):653-80. doi: 10.2165/00003495-200059030-00016.
Armstrong T, Fenn SJ, Hardie KR. JMM Profile: Carbapenems: a broadspectrum antibiotic. J Med Microbiol. 2021;70(12):001462. doi: 10.1099/ jmm.0.001462.
Wright GD. Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev. 2005;29;57(10):1451-70.
Caruso C, Valluzzi RL, Colantuono S, Gaeta F, Romano A. β-Lactam Allergy and Cross-Reactivity: A Clinician’s Guide to Selecting an Alternative Antibiotic. J Asthma Allergy. 2021; 14:31-46.
Pařízková RČ, Martínková J, Havel E, Šafránek P, Kaška M, Astapenko D, Bezouška J, Chládek J, Černý V. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis. Crit Care. 2021 Jul 17;25(1):251. doi: 10.1186/s13054-021-03680-9. PMID: 34274013; PMCID: PMC8285835.
Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992 Dec;36(12):2794-8. doi: 10.1128/AAC.36.12.2794. PMID: 1482147; PMCID: PMC245547.
Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992 Jul;36(7):1532-7. doi: 10.1128/AAC.36.7.1532. PMID: 1510451; PMCID: PMC191616.
Simon P, Petroff D, Busse D, Heyne J, Girrbach F, Dietrich A, Kratzer A, Zeitlinger M, Kloft C, Kees F, Wrigge H, Dorn C. Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients-A Controlled Clinical Trial. Antibiotics (Basel). 2020 Dec 21;9(12):931. doi: 10.3390/antibiotics9120931. PMID: 33371322; PMCID: PMC7767385.
Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis. 1999;31(1):3-10. doi: 10.1080/00365549950161808.
Shah D, Narang M. Meropenem. Indian Pediatr. 2005 May;42(5):443-50. PMID: 15923690.
Hnat M, Bawdon RE. Transfer of meropenem in the ex vivo human placenta perfusion model. Infect Dis Obstet Gynecol. 2005 Dec;13(4):223-7. doi: 10.1080/10647440500147992. PMID: 16338783; PMCID: PMC1784578.
Tchirikov M, Ocker R, Seliger G, Chaoui K, Moritz S, Haase R. Treatment of mid-trimester preterm premature rupture of membranes (PPROM) with multi-resistant bacteria-colonized anhydramnion with continuous amnioinfusion and meropenem: a case report and literature review. Arch Gynecol Obstet. 2021 Nov 18:1–8. doi: 10.1007/s00404-021-06319-w. Epub ahead of print. PMID: 34791511; PMCID: PMC8598399.
Chimura T, Murayama K, Oda T, Igarashi Y, Morisaki N, Hirayama T, Kihara K. [Clinical effects of meropenem on infectious diseases in obstetrics and gynecology]. Jpn J Antibiot. 2001 Jan;54(1):1-7. Japanese. PMID: 11268733.
Esposito S, Pinzani R, Raffaeli G, Lucchi T, Agostoni C, Principi N. A young infant with transient severe hypertriglyceridemia temporarily associated with meropenem administration: A case report and review of the literature. Medicine (Baltimore). 2016 Sep;95(38):e4872. doi: 10.1097/ MD.0000000000004872. PMID: 27661029; PMCID: PMC5044899.
Sauberan JB, Bradley JS, Blumer J, Stellwagen LM. Transmission of meropenem in breast milk. Pediatr Infect Dis J. 2012 Aug;31(8):832-4. doi: 10.1097/INF.0b013e318256f4bf. PMID: 22544050.
Product Information: MERREM(R) intravenous injection, meropenem intravenous injection. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2013.
Product Information: MERREM(R) IV intravenous injection, meropenem intravenous injection. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2018.
